Arecor Limited, located on the Cambridge Science Park, was established to provide formulation solutions to pharmaceutical and biotech companies developing drugs, vaccines, medical devices and diagnostics.
|Address:||Chesterford Research Park, Little Chesterford, Saffron Walden|
|Membership type:||Corporate 6-20 (£250+VAT pa)|
A UK-based leading formulation technology company delivering superior biopharmaceuticals via the innovative reformulation of proteins and peptides.
Arecor is a leader in developing superior biopharmaceuticals through the application of its innovative formulation technology platform. Arecor is leveraging this platform to develop a portfolio of proprietary products enabling improved treatments for diabetes care via the innovative reformulation of approved proteins and peptides.
In addition to its internal product portfolio, Arecor partners with leading pharmaceutical and biotech companies to deliver superior reformulations of their proprietary products, which would otherwise not be possible using conventional formulation science.
“The Company features alongside The Prime Minister, The Rt Hon Theresa May MP, and a small number of outstanding organisations in the Technology edition”
4 October 2017Read in full
Arecor Ltd (“the Company”), the leading formulation technology company, focussed on developing superior biopharmaceuticals via the innovative reformulation of proteins and peptides to improve the treatment of diabetes and other conditions, is pleased to announce that a global pharmaceutical and healthcare company, has exercised its license option to Arecor’s proprietary formulation technology, to develop differentiated biosimilar products.
3 October 2017Read in full
Arecor Ltd, the leading formulation technology company, focused on developing superior biopharmaceuticals to improve the treatment of diabetes and other conditions, announces the inaugural formation of a Global Diabetes Scientific Advisory Board (SAB) to support the scientific, pre-clinical and clinical development of its proprietary superior diabetes products to better improve the quality of life of those living with diabetes.
12 September 2017Read in full
Arecor Ltd, the leading formulation technology company focused on developing superior biopharmaceuticals to improve the treatment of diabetes and other conditions, is pleased to announce the appointment of Dr Sam Fazeli as Non-Executive Director of the Company.
7 September 2017Read in full
Arecor Ltd is celebrating its 10th year and to mark the occasion it is holding a 40Km and 80Km charity cycle ride, raising funds and awareness for the JDRF organisation.
11 July 2017Read in full
Arecor's prototype liquid glucagon product shows stability and commercial viability; partnership with Innovate UK aims to accelerate pre-clinical asset towards proof-of-concept and first-in-human trials.
2 February 2017Read in full
JDRF announces partnership with Arecor Ltd to support development of a stable, rapid-acting, ultra-concentrated insulin.
25 July 2016Read in full
Arecor Limited, which provides advanced formulation technology to the pharmaceutical industry, have been awarded a SMART award from Innovate UK, the UK’s innovation agency, to develop and demonstrate an ultra-long acting basal insulin to combat the risk of nocturnal hypoglycaemia in diabetic patients, improving patient safety and compliance.
6 June 2016Read in full
Arecor, CPI and FUJIFILM Diosynth Biotechnologies collaborate to apply smart formulation approaches in the manufacturing of biopharmaceuticals under a grant awarded by Innovate UK.
12 November 2015Read in full